NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

斯特格氏病治療藥的全球市場 - 藥物的各類型、各年齡層 (兒童,成人)、各流通管道、各地區:市場規模、佔有率、未來展望、機會分析 (2020年∼2027年)

Stargardt Disease Therapeutics Market, By Drug Type, By Age Group (Children, Adult ), By Distribution Channel, By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 1009421
出版日期 內容資訊 英文 167 Pages
商品交期: 2-3個工作天內
價格
斯特格氏病治療藥的全球市場 - 藥物的各類型、各年齡層 (兒童,成人)、各流通管道、各地區:市場規模、佔有率、未來展望、機會分析 (2020年∼2027年) Stargardt Disease Therapeutics Market, By Drug Type, By Age Group (Children, Adult ), By Distribution Channel, By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2021年05月10日內容資訊: 英文 167 Pages
簡介

斯特格氏病,又稱斯特格氏黃斑失養症 (SMD),約10,000人中有1人患病,生命早期階段產生中樞性視力喪失。全球斯特格氏病治療藥市場,今後隨著開發中產品臨床實驗的進展和上市,患病者增加,預計市場規模擴大。

本報告提供全球斯特格氏病治療藥的市場相關分析,疾病、產品概要,及市場基本結構及促進、阻礙因素,整體市場規模預測,藥物的各類型、各年齡層、各流通管道、各地區的詳細趨勢,主要企業的簡介、業績、策略計劃等調查。

目錄

第1章 分析目的、前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場力學、規定、趨勢分析

  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 影響度分析
  • 開發平台分析
  • 斯特格氏病的診斷法
  • 斯特格氏病的治療方法
  • 法規方案
  • 近幾年主要的動向
  • 近來的產品核可/上市
  • 企業合併、收購 (M&A),契約
  • PEST分析
  • 流行病學

第4章 全球斯特格氏病治療藥市場:新型冠狀病毒感染疾病 (COVID-19) 感染擴大的影響

  • COVID-19:醫療產業整體的影響
  • COVID-19流行病學
  • 需求與供給分析
  • COVID-19對臨床實驗和醫藥品開發的影響
  • 為了實施現在進行中的臨床實驗採取的舉措

第5章 全球斯特格氏病治療藥市場:藥物的各類型 (以金額為準,2023年∼2028年)

  • 簡介
  • Emixustat
  • LBS-008

第6章 全球斯特格氏病治療藥市場:各年齡層 (以金額為準,2023年∼2028年)

  • 簡介
  • 兒童 (不滿17歲)
  • 成人 (17歲以上)

第7章 全球斯特格氏病治療藥市場:各流通管道 (以金額為準,2023年∼2028年)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球斯特格氏病治療藥市場:各地區 (以金額為準,2023年∼2028年)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Stargazer Pharmaceuticals Inc.
    • Iveric Bio, Inc.
    • Sanofi SA
    • Alkeus Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • CHABiotech CO., Ltd
    • ReVision Therapeutics, Inc.
    • Lin BioScience, Inc.
    • Biogen Inc.
    • F. Hoffmann-La Roche AG

第10章 附錄

目錄

Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.

Market Dynamics

The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.

Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech's orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company's C5 complement inhibitor, for Stargardt disease.

Key features of the study:

  • This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Global Stargardt Disease Therapeutics Market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .

Detailed Segmentation:

  • Global Stargardt Disease Therapeutics Market , By Drug Type:
    • Emixustat
    • LBS-008
  • Global Stargardt Disease Therapeutics Market , By Age Group:
    • Children (Below17 Years)
    • Adult (Above 17 Years)
  • Global Stargardt Disease Therapeutics Market , By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Stargardt Disease Therapeutics Market , By Region:
    • North America
      • By Drug Type
      • Emixustat
      • LBS-008
      • By Age Group
      • Children (Below17 Years)
      • Adult (Above 17 Years)
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Drug Type
      • Emixustat
      • LBS-008
      • By Age Group
      • Children (Below17 Years)
      • Adult (Above 17 Years)
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type
      • Emixustat
      • LBS-008
      • By Age Group
      • Children (Below17 Years)
      • Adult (Above 17 Years)
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type
      • Emixustat
      • LBS-008
      • By Age Group
      • Children (Below17 Years)
      • Adult (Above 17 Years)
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type
      • Emixustat
      • LBS-008
      • By Age Group
      • Children (Below17 Years)
      • Adult (Above 17 Years)
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type
      • Emixustat
      • LBS-008
      • By Age Group
      • Children (Below17 Years)
      • Adult (Above 17 Years)
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Kubota Pharmaceutical Holdings Co., Ltd.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Stargazer Pharmaceuticals Inc.
    • Iveric Bio, Inc.
    • Sanofi S.A.
    • Alkeus Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • CHABiotech CO., Ltd
    • ReVision Therapeutics, Inc.
    • Lin BioScience, Inc.
    • Biogen Inc.
    • F. Hoffmann-La Roche AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Age Group
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunity
  • Impact Analysis
  • Pipeline Analysis
  • Diagnosis of Stargardt Disease
  • Treatment of Stargardt Disease
  • Regulatory Scenario
  • Key Developments
  • Recent Approvals / Launches
  • Merger, Acquisitions, and Agreement
  • PEST Analysis
  • Epidemiology

4. Global Stargardt Disease Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Impact on Overall the Healthcare Sector
  • COVID-19 Epidemiology
  • Supply and Demand Analysis
  • COVID-19 Impact on Clinical Trials and Drug Development
  • Initiatives Taken to Conduct Ongoing Clinical Trials

5. Global Stargardt Disease Therapeutics Market , By Drug Type, 2023 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2028 (%)
    • Y-o-Y Growth Analysis, 2024 - 2028
    • Segment Trends
  • Emixustat
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)
  • LBS-008
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)

6. Global Stargardt Disease Therapeutics Market , By Age Group, 2023 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2028 (%)
    • Y-o-Y Growth Analysis, 2024 - 2028
    • Segment Trends
  • Children (Below17 Years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)
  • Adult (Above 17 Years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)

7. Global Stargardt Disease Therapeutics Market , By Distribution Channel, 2023 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2028 (%)
    • Y-o-Y Growth Analysis, 2024 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2028, (US$ Mn)

8. Global Stargardt Disease Therapeutics Market , By Region, , 2023 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2028 (%)
    • Y-o-Y Growth Analysis, 2024 - 2028
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2028, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Kubota Pharmaceutical Holdings Co., Ltd.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Stargazer Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Iveric Bio, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Alkeus Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • CHABiotech CO., Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • ReVision Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Lin BioScience, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies

10. Section

  • Research Methodology
  • About us